100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

被引：30
|
作者：
Bronowicki, J-P [1 ]
Hezode, C. [2 ]
Bengtsson, L. [3 ]
Pol, S. [4 ]
Bourliere, M. [5 ]
Serfaty, L. [6 ]
de Ledinghen, V. [7 ]
Tran, A. [8 ]
Benhamou, Y. [9 ]
Grange, J-D [10 ]
Mathurin, P. [11 ]
Marcellin, P. [12 ]
Trepo, C. [13 ]
Zarski, J-P [14 ]
Seepersaud, S. [3 ]
Kelliher, K. [3 ]
Botfield, M. [3 ]
Pawlotsky, J-M [2 ]
机构：
[1] CHU Nancy, INSERM, U954, Nancy, France
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Vertex Pharmaceut Inc, Cambridge, MA USA
[4] Hop Cochin, F-75674 Paris, France
[5] Hop St Joseph, Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] CHU Bordeaux, Bordeaux, France
[8] CHU Nice, Nice, France
[9] Hop La Pitie Salpetriere, Paris, France
[10] Hop Tenon, F-75970 Paris, France
[11] CHU Lille, F-59037 Lille, France
[12] Hop Beaujon, Clichy, France
[13] CHU Lyon, Lyon, France
[14] CHU Grenoble, F-38043 Grenoble, France
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61106-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1094
引用
收藏
页码：S430 / S431
页数：2
相关论文
共 50 条
  • [1] ALL IL28B GENOTYPES HAVE HIGH SVR RATES IN PATIENTS TREATED WITH VX-222 IN COMBINATION WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE ZENITH STUDY
    Penney, M. S.
    De Souza, C.
    Seepersaud, S.
    Alves, K.
    Koziel, M. J.
    Kauffman, R. S.
    Di Bisceglie, A. M.
    Botfield, M. C.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S476 - S477
  • [2] SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
    Pol, S.
    Aerssens, J.
    Zeuzem, S.
    Andreone, P.
    Lawitz, E. J.
    Roberts, S.
    Younossi, Z.
    Foster, G. R.
    Focaccia, R.
    Horban, A.
    Pockros, P. J.
    Van Heeswijk, R.
    de Meyer, S.
    Luo, D.
    Botfield, M.
    Beumont, M.
    Picchio, G.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S6 - S7
  • [3] Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study
    Younossi, Zobair M.
    Aerssens, Jeroen
    Pol, Stanislas
    Pockros, Paul
    Lawitz, Eric J.
    Zeuzem, Stefan
    Andreone, Pietro
    Roberts, Stuart K.
    Foster, Graham
    Focaccia, Roberto
    Horban, Andrzej
    van Heeswijk, Roll
    De Meyer, Sandra
    Luo, Don
    Botfield, Martyn C.
    Beumont-Mauviel, Maria
    Picchio, Gaston
    GASTROENTEROLOGY, 2011, 140 (05) : S907 - S908
  • [4] SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
    Muellhaupt, Beat
    Pol, Stanislas
    Aerssens, Jeroen
    Zeuzem, Stefan
    Andreone, Pietro
    Lawitz, Eric J.
    Roberts, Stuart
    Younossi, Zobair
    Foster, Graham R.
    Focaccia, Roberto
    Horban, Andrzej
    Pockros, Paul J.
    Van Heeswijk, Rolf
    de Meyer, Sandra
    Luo, Donghan
    Beumont, Maria
    Picchio, Gaston
    SWISS MEDICAL WEEKLY, 2011, 141 : 6S - 7S
  • [5] SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
    Foster, G. R.
    Pol, S.
    Aerssens, J.
    Zeuzem, S.
    Andreone, P.
    Lawitz, E. J.
    Roberts, S.
    Younossi, Z.
    Focaccia, R.
    Horban, A.
    Pockros, P. J.
    Van Heeswijk, R.
    de Meyer, S.
    Luo, D.
    Beumont, M.
    Picchio, G.
    GUT, 2011, 60 : A55 - A55
  • [6] Sustained Virological Response After 4 Weeks of Telaprevir, Peginterferon, and Ribavirin in an Asian Patient with Genotype 1 Chronic Hepatitis C and IL28B Genotype CC
    Natalie Brulotte
    Hejin Hahn
    Maximilian Lee
    Digestive Diseases and Sciences, 2014, 59 : 737 - 739
  • [7] Sustained Virological Response After 4 Weeks of Telaprevir, Peginterferon, and Ribavirin in an Asian Patient with Genotype 1 Chronic Hepatitis C and IL28B Genotype CC
    Brulotte, Natalie
    Hahn, Hejin
    Lee, Maximilian
    DIGESTIVE DISEASES AND SCIENCES, 2014, 59 (04) : 737 - 739
  • [8] GS-5885+GS-9451+PEGINTERFERON AND RIBAVIRIN (PR) FOR SIX OR TWELVE WEEKS ACHIEVES HIGH SVR12 RATES IN TREATMENT-NAIVE GENOTYPE 1 IL28B CC PATIENTS
    Thompson, A.
    Han, S.
    Shiffman, M. L.
    Rossaro, L.
    Ghalib, R.
    Beavers, K.
    Pianko, S.
    Wu, X.
    Pang, P. S.
    Rossi, S.
    McHutchison, J.
    Muir, A.
    Lee, S.
    George, J.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S29 - S29
  • [9] Ledipasvir + GS-9451+peginterferon and ribavrin (PR) for six or 12 weeks achieves a high SVR12 in treatment naive genotype 1 IL28B CC patients
    Thompson, A.
    Shiffman, M.
    Pianko, S.
    Kanwar, B.
    Mchutchison, J.
    Muir, A. J.
    Lee, S.
    George, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 173 - 173
  • [10] TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
    Jacobson, I. M.
    Catlett, I.
    Marcellin, P.
    Bzowej, N. H.
    Muir, A. J.
    Adda, N.
    Bengtsson, L.
    George, S.
    Seepersaud, S.
    Ramachandran, R.
    Sussky, K.
    Kauffman, R. S.
    Botfield, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S542 - S543
12345